Trial intelligence / Profile preview

CASPER-ATG-IPC: Low-dose thymoglobulin after haploidentical HSCT in elderly patients

2023-506648-18-00Phase 2Authorised

Sponsor: Institut Paoli-Calmettes
Start: Jun 2024
Modality: Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, open-label, single-arm trial of antithymocyte globulin rabbit in hematopoietic malignancies, leukemia, lymphoma and 1 more, sponsored by Institut Paoli-Calmettes. Primary endpoint: Incidence of grade 2-4 acute GVHD at day 100 post-transplant. Planned start Jun 2024; status: authorised.

Drugs

antithymocyte globulin rabbit

Conditions

hematopoietic malignanciesleukemialymphomamultiple myeloma (MM)

Beyond the preview

Go deeper on 2023-506648-18-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-506648-18-00.